European perspective on multiple myeloma treatment strategies in 2014.
暂无分享,去创建一个
H. Goldschmidt | G. Morgan | M. Dimopoulos | H. Einsele | P. Sonneveld | M. Boccadoro | T. Plesner | R. Hájek | H. Nahi | P. Moreau | F. Davies | H. Ludwig | M. Delforge | T. Facon | J. San-Miguel | J. Bladé | J. de la Rubia | A. Palumbo | M. Cavo | P. Sondergeld | Pia Sondergeld
[1] E. Grove,et al. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. , 2014, Thrombosis research.
[2] K. Knopf,et al. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. , 2014, Clinical lymphoma, myeloma & leukemia.
[3] Christian Jacques,et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. , 2014, The New England journal of medicine.
[4] H. Goldschmidt,et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Drayson,et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[6] D. Esseltine,et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. , 2014, Blood.
[7] M. Boccadoro,et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Haggarty,et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma , 2014, Leukemia.
[9] Michele Cavo,et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Greil,et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. , 2014, Blood.
[11] E. Giné,et al. Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma , 2014, Bone Marrow Transplantation.
[12] N. Puig,et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry , 2014, Leukemia.
[13] H. Goldschmidt,et al. IMWG consensus on risk stratification in multiple myeloma , 2014, Leukemia.
[14] M. Beksac,et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma , 2014, Haematologica.
[15] B. Barlogie,et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). , 2014, Blood.
[16] M. Bhutani,et al. Smoldering multiple myeloma: present position and potential promises , 2014, European journal of haematology.
[17] M. Kersten,et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial , 2014, Haematologica.
[18] A. Krishnan,et al. SECOND TRANSPLANTS FOR MULTIPLE MYELOMA RELAPSING AFTER A PRIOR AUTOTRANSPLANT – REDUCED INTENSITY ALLOGENEIC VERSUS AUTOLOGOUS TRANSPLANTATION , 2013, Bone Marrow Transplantation.
[19] S. Vincent Rajkumar,et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.
[20] P. L. Bergsagel,et al. Smoldering multiple myeloma requiring treatment: time for a new definition? , 2013, Blood.
[21] J. Sloan,et al. Treatment trade‐offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies , 2013, Cancer.
[22] J. Besalduch,et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent‐PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study , 2013, British journal of haematology.
[23] R. Bataille,et al. Multiple myeloma international staging system: "staging" or simply "aging" system? , 2013, Clinical lymphoma, myeloma & leukemia.
[24] C. Flowers,et al. Bortezomib‐containing induction regimens in transplant‐eligible myeloma patients , 2013, Cancer.
[25] A. Roberts,et al. Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study , 2013 .
[26] M. Boccadoro,et al. Persistent Improvement In Clinical Outcomes With Bortezomib-Thalidomide-Dexamethasone Vs Thalidomide-Dexamethasone Incorporated Into Double Autologous Transplantation For Multiple Myeloma: An Updated Analysis Of Phase 3 Gimema-MMY-3006 Study , 2013 .
[27] J. Reeves,et al. Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416) , 2013 .
[28] B. Pégourié,et al. Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14) , 2013 .
[29] A. Hui,et al. Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data , 2013 .
[30] P. Sonneveld,et al. Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age , 2013 .
[31] M. Kersten,et al. Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial , 2013 .
[32] M. Boccadoro,et al. Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients , 2013 .
[33] Wei Zheng,et al. SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study , 2013 .
[34] H. Goldschmidt,et al. Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies , 2013 .
[35] P. Moreau,et al. Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial , 2013 .
[36] V. Pavone,et al. A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients , 2013 .
[37] M. Boccadoro,et al. A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients , 2013 .
[38] R. Orlowski,et al. Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study , 2013 .
[39] S. Lonial,et al. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma , 2013, Expert opinion on biological therapy.
[40] A. Krishnan,et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[41] Michael L. Wang,et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. , 2013, Blood.
[42] F. Davies,et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study , 2013, Supportive Care in Cancer.
[43] R. Wäsch,et al. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. , 2013, Clinical lymphoma, myeloma & leukemia.
[44] Linda Z. Sun,et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. , 2013, The Lancet. Oncology.
[45] H. Goldschmidt,et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.
[46] T. Guglielmelli,et al. Incorporating Novel Agents in the Management of Elderly Myeloma Patients , 2013, Current Hematologic Malignancy Reports.
[47] D. Esseltine,et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] G. Morgan,et al. Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.
[49] J. S. San Miguel,et al. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post‐allogeneic transplantation for high‐risk myeloma patients , 2013, British journal of haematology.
[50] F. Prósper,et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. , 2013, The New England journal of medicine.
[51] K. Akashi,et al. Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma , 2013, International Journal of Hematology.
[52] G. Morgan,et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. , 2013, Blood.
[53] N. Munshi,et al. Minimal Residual Disease in Multiple Myeloma , 2018 .
[54] K. Anderson,et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. , 2013, Leukemia research.
[55] H. Prince,et al. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma , 2013, Leukemia & lymphoma.
[56] G. Kobbe,et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[57] D. Hose,et al. Autologous retransplantation for patients with recurrent multiple myeloma , 2013, Cancer.
[58] M. Beksac,et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. , 2013, Blood.
[59] G. Morgan,et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] S. Jagannath,et al. Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety. , 2013 .
[61] F. Pépin,et al. Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma. , 2013 .
[62] B. Barlogie,et al. Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD). , 2013 .
[63] J. Vose,et al. Salvage second hematopoietic cell transplantation in myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[64] A. Belch,et al. Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma. , 2013, The oncologist.
[65] D. Dingli,et al. Second auto-SCT for treatment of relapsed multiple myeloma , 2013, Bone Marrow Transplantation.
[66] P. Moreau,et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[67] N. Kröger,et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[68] P. Sonneveld,et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials , 2013, Haematologica.
[69] Benjamin Djulbegovic,et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials , 2013, Journal of Hematology & Oncology.
[70] A. Stewart. Erratum: Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013 (Mayo Clinic Proceedings (2013) 88:4 (360-376)) , 2013 .
[71] A. Krishnan,et al. Multiple myeloma, version 1.2013. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.
[72] C. Solano,et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[73] L. Garrison,et al. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. , 2013, The oncologist.
[74] R. Mina,et al. Management of older adults with multiple myeloma. , 2013, Blood reviews.
[75] P. L. Bergsagel,et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. , 2013, Mayo Clinic proceedings.
[76] J. Endell,et al. The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo , 2012 .
[77] J. Miguel,et al. Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial , 2012 .
[78] M. Dimopoulos,et al. Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial , 2012 .
[79] P. Richardson,et al. Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study , 2012 .
[80] Frauke Naumann-Winter,et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. , 2012, The Cochrane database of systematic reviews.
[81] J. Laubach,et al. New Proteasome Inhibitors in Myeloma , 2012, Current Hematologic Malignancy Reports.
[82] Michael L. Wang,et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. , 2012, Blood.
[83] A. Oriol,et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. , 2012, Blood.
[84] M. Kaminski,et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. , 2012, Blood.
[85] A. Oriol,et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. , 2012, Blood.
[86] M. Kersten,et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] Michele Cavo,et al. Proteasome inhibitors in multiple myeloma: 10 years later. , 2012, Blood.
[88] M. Boccadoro,et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. , 2012, Blood.
[89] D. Blaise,et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. , 2012, Experimental hematology.
[90] A. Jakubowiak. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. , 2012, Seminars in hematology.
[91] P. Moreau. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. , 2012, Seminars in hematology.
[92] M. Kersten,et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. , 2012, Blood.
[93] S. Jagannath,et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] M. Beksac,et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.
[95] Sharmila Bhattacharya,et al. Physiological Changes Associated with Aging and Immobility , 2012, Journal of aging research.
[96] S. Trudel,et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[97] H. Goldschmidt,et al. MyelomA Genetics International Consortium , 2012, Leukemia & lymphoma.
[98] H. Goldschmidt,et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. , 2012, The oncologist.
[99] D. Dingli,et al. Early versus delayed autologous transplantation after immunomodulatory agents‐based induction therapy in patients with newly diagnosed multiple myeloma , 2012, Cancer.
[100] G. Morgan,et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. , 2012, Blood.
[101] M. Terol,et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. , 2012, Blood.
[102] N. Geller,et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. , 2011, The Lancet. Oncology.
[103] R. Fanin,et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. , 2011, Blood.
[104] M. Boccadoro,et al. Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study , 2011 .
[105] G. Morgan,et al. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[106] G. Morgan,et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). , 2011, Blood.
[107] B. Barlogie,et al. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma , 2011, International journal of hematology.
[108] J. San-Miguel,et al. Can multiple myeloma become a curable disease? , 2011, Haematologica.
[109] H. Goldschmidt,et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] D. Esseltine,et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma , 2011, European journal of haematology.
[111] D. Esseltine,et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.
[112] A. Órfão,et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] P. Sonneveld,et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.
[114] S. Lonial,et al. Treatment Options for Relapsed and Refractory Multiple Myeloma , 2011, Clinical Cancer Research.
[115] K. Anderson,et al. Antibody-Based Therapies in Multiple Myeloma , 2011, Bone marrow research.
[116] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[117] J. Connors,et al. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months) , 2011, Leukemia & lymphoma.
[118] R. Fanin,et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. , 2010, Blood.
[119] N. Munshi,et al. Management of relapsed and relapsed/refractory multiple myeloma. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[120] M. Baccarani,et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.
[121] R. Greil,et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] M. Mohty,et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[123] H. Einsele,et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] F. Prósper,et al. Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma , 2010, Clinical Cancer Research.
[125] B. Barlogie,et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] I. Turesson,et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] B. Pégourié,et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). , 2010, Blood.
[128] Robert A Kyle,et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.
[129] O. Witt,et al. HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.
[130] A. Órfão,et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.
[131] I. Yakoub-Agha,et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. , 2008, Blood.
[132] J. S. San Miguel,et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. , 2008, Blood.
[133] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[134] H. Brenner,et al. Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.
[135] R. Fanin,et al. A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.
[136] J. Bourhis,et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. , 2006, Blood.
[137] B. Barlogie,et al. Cure of myeloma: hype or reality? , 2005, Bone Marrow Transplantation.